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PNPLA3 variant and portal/
periportal histological pattern in 
patients with biopsy-proven non-
alcoholic fatty liver disease: a 
possible role for oxidative stress
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Maria Del Ben2, Marcello Arca2, Francesco Violi2, Francesco Angelico6 & Eugenio Gaudio3
Pathogenesis of non-alcoholic fatty liver disease (NAFLD) is influenced by predisposing genetic 
variations, dysmetabolism, systemic oxidative stress, and local cellular and molecular cross-talks. 
Patatin-like phospholipase domain containing 3 (PNPLA3) gene I148M variant is a known determinant 
of NAFLD. Aims were to evaluate whether PNPLA3 I148M variant was associated with a specific 
histological pattern, hepatic stem/progenitor cell (HpSC) niche activation and serum oxidative stress 
markers. Liver biopsies were obtained from 54 NAFLD patients. The activation of HpSC compartment 
was evaluated by the extension of ductular reaction (DR); hepatic stellate cells, myofibroblasts (MFs), 
and macrophages were evaluated by immunohistochemistry. Systemic oxidative stress was assessed 
measuring serum levels of soluble NOX2-derived peptide (sNOX2-dp) and 8-isoprostaglandin F2α (8-iso-
PGF2α). PNPLA3 carriers showed higher steatosis, portal inflammation and HpSC niche activation 
compared to wild-type patients. DR was correlated with NAFLD activity score (NAS) and fibrosis score. 
Serum 8-iso-PGF2α were significantly higher in I148M carriers compared to non-carriers and were 
correlated with DR and portal inflammation. sNox2-dp was correlated with NAS and with HpSC niche 
activation. In conclusion, NAFLD patients carrying PNPLA3 I148M are characterized by a prominent 
activation of HpSC niche which is associated with a more aggressive histological pattern (portal 
fibrogenesis) and increased oxidative stress.
Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease worldwide1. 
NAFLD includes a spectrum of diseases ranging from simple fatty liver to non-alcoholic steatohepatitis (NASH) 
and may progress to cirrhosis and hepatocellular carcinoma1. The pathogenesis of NAFLD is multifactorial and 
could be influenced by predisposing genetic variations, dysmetabolic conditions, systemic oxidative stress, and 
local cellular and molecular cross-talks2.
The single nucleotide polymorphism in residue 148 (I148M, rs738409) in human patatin-like phospholipase 
domain containing 3 (PNPLA3) gene, which exhibits a C-to-G transition resulting in an amino acid substitu-
tion of isoleucine to methionine, is one of the strongest genetic determinants of NAFLD3–5. This mutation was 
suggested to impair triglyceride hydrolysis and potentially explain the increased triglyceride accumulation in 
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hepatocytes4. Moreover, PNPLA3 variants have been associated with a worse histological depict in NAFLD6; 
however, no studies investigated the potential influence of PNPLA3 I148M variant in the development of spe-
cific histological pattern and in the intricate cross-talks between different cellular compartments activated by the 
regenerative response to liver damage in NAFLD.
In fact, the progression of NAFLD is determined by interactions between resident and recruited cells7. 
Triglyceride accumulation and the consequent long-lasting oxidative stress induce apoptosis and cell cycle arrest 
in hepatocytes, thus triggering the activation of the facultative Hepatic stem/progenitor cell (HpSC) niche8,9. The 
HpSC niche is composed by macrophages, Hepatic Stellate Cells (HSCs), and well-defined extracellular matrix 
compounds. Remarkably, HpSC response is influenced by macrophage subsets10–13; in turn, HpSC proliferation 
can activate HSCs, thus participating in fibrogenesis and leading to portal fibrosis14.
Therefore, the aims of the present study have been to evaluate whether NAFLD patients carrying PNPLA3 
I148M variant: i) showed a specific histological pattern at liver biopsy; ii) were characterized by a prominent acti-
vation of HpSC niche; iii) presented increased levels of serum systemic oxidative stress markers.
Results
Anthropometric, clinical and genetic parameters. Anthropometric and clinical characteristics of 
patients are listed in Table 1. Mean age was 48.6 ± 12.4 years, and 48.1% were women. Mean Body Mass Index 
(BMI) was 29.3 ± 4.2 Kg/m2, 47.5% suffered from arterial hypertension and 40.0% from diabetes. As regard 
PNPLA3, 39/54 (72%) patients carried at least one allele with the I148M variant while 15/54 (28%) patients have 
a wild-type (WT) genotype. Patients with and without PNPLA3 I148M variant had similar characteristics, with 
the exception for arterial hypertension, which was less prevalent in patients with I148M variant (Table 1).
Histo-pathological analysis. Liver biopsies were classified into SS (simple steatosis; N = 25), NASH (defi-
nite steatohepatitis; N = 25), and borderline, zone 3 pattern (N = 4). The NAFLD Activity Score (NAS) ranged 
from 1 to 8. Fibrosis of some degree was seen in 51/54 biopsy samples: stage 1 in 13 samples, stage 2 in 21, stage 3 
in 14, and stage 4 in 3. Portal inflammation was seen in 26/54 biopsy samples: 8/25 (32%) SS biopsies and in 16/25 
(64%) NASH biopsies (p = 0.023). Biopsies with NASH showed significantly higher steatosis, inflammation, hepa-
tocellular ballooning, and NAS score when compared to biopsies with SS (Table 2, Fig. 1). Furthermore, NASH 
biopsies showed higher fibrosis score when compared to SS biopsies (Table 2 and Fig. 1). NAS score was directly 
correlated with fibrosis score (r = 0.484; p = 0.000).
HpSC activation. When histologic classification was considered (Fig. 2A), DR extension was higher in 
NASH biopsies when compared with SS ones (Table 2; p = 0.005). EpCAM+ hepatocytes were found in 7/25 SS 
biopsies; contrarily, single occasional or clusters of EpCAM+ hepatocytes were present in 15/25 NASH biopsies 
(Fig. 2B).
NAFLD (n = 54)
Wild type (CC 
carrier) (n = 15)
PNPLA3 (GC/GG 
variant carrier) (n = 39) p-value
Age (years) 48.6 ± 12.4 51.7 ± 47.3 47.3 ± 12.6 0.307
Women (%) 48.1 40.0 51.3 0.731
Current cigarette smokers (%) 32.5 33.3 32.1 1.000
Arterial hypertension (%) 47.5 83.3 32.1 <0.05
Diabetes Mellitus (%) 40.0 25.0 46.4 0.297
Body Mass Index (kg/m2) 29.3 ± 4.2 29.0 ± 3.5 29.4 ± 4.5 0.785
Waist circumference (cm) 104.1 ± 10.3 103.7 ± 9.9 104.2 ± 10.7 0.889
Metabolic syndrome (%) 59.0 60.0 59.0 0.598
Fasting plasma glucose (mg/dl) 105.9 ± 36.4 96.7 ± 16.5 110.1 ± 42.2 0.295
Total cholesterol (mg/dl) 195.3 ± 36.8 189.9 ± 38.7 197.6 ± 36.6 0.569
Low density lipoprotein (mg/dl) 116.1 ± 30.6 111.4 ± 40.9 117.9 ± 26.4 0.574
High density lipoprotein (mg/dl) 48.5 ± 22.8 43.0 ± 9.0 50.7 ± 26.3 0.350
Triglycerides (mg/dl) 157.4 ± 103.0 163.2 ± 72.8 155.1 ± 114.1 0.830
Statin (%) 19.4 16.7 20.8 1.000
Aspartate aminotransferase (U/l) 49.9 ± 33.1 39.2 ± 17.7 54.4 ± 37.2 0.089
Alanine aminotransferase (U/l) 82.2 ± 48.2 62.2 ± 32.9 90.8 ± 51.6 <0.05
GGT (U/l) 71.4 ± 57.0 74.2 ± 79.7 70.2 ± 46.0 0.845
Creatinine (mg/dl) 0.8 ± 0.2 0.8 ± 0.1 0.8 ± 0.2 0.699
sNox2-dp (pg/ml) 37.2 ± 15.0 33.8 ± 10.3 38.7 ± 16.6 0.270
Serum F2-Isoprostanes (pg/ml) 70.1 ± 11.7 64.4 ± 14.8 72.5 ± 9.4 <0.05
Table 1. Clinical characteristics of NAFLD patients according to the PNPLA3 genotype. Data are reported as 
mean ± standard deviation. p value in bold are statistically significant. NAFLD: nonalcoholic fatty liver disease; 
PNPLA3: patatin-like phospholipase domain containing 3; GGT: Gamma-glutamyltranspeptidase; sNox2-dp: 
soluble Nox2-derived peptide.
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DR extension was significantly correlated with NAS (r = 0.469; p = 0.001), fibrosis score (r = 0.439; 
p = 0.003), and with the presence of EpCAM+ hepatocytes (r = 0.578; p = 0.000). Furthermore, the presence of 
EpCAM+ hepatocytes was significantly correlated with NAS score (r = 0.509, p = 0.000) and fibrosis (r = 0.482; 
p = 0.001).
HSC/MF pool activation. The activation of HSC/MF pool was evaluated by immunohistochemistry for 
αSMA (Fig. 1). The number of αSMA+ pericentral HSCs was increased in NASH biopsies in comparison with 
SS ones (Table 2; p = 0.024); similarly, the number of αSMA+ portal/septal MFs was increased in NASH in 
comparison with SS biopsies (Table 2; p = 0.034). The number of αSMA+ pericentral HSCs was correlated with 
the number of αSMA+ portal/septal MFs (r = 0.672; p = 0.000). Furthermore, the number of αSMA+ pericen-
tral HSCs was correlated with NAS (r = 0.353; p = 0.014) and fibrosis score (r = 0.385; p = 0.007) but not with 
DR. The number of αSMA+ portal/septal MFs was correlated with NAS (r = 0.344; p = 0.017), fibrosis score 
(r = 0.383; p = 0.007), portal inflammation (r = 0.357; p = 0.013), and DR (r = 0.526; p = 0.001). Multivariate 
analysis revealed that the number of αSMA+ portal/septal MFs is independently associated with DR (p = 0.028) 
irrespectively to the other histo-morphological parameters (NAS, fibrosis score, steatosis, lobular inflammation, 
ballooning, and portal inflammation).
Macrophage pool. The number of portal but not lobular S100A9+ (pro-inflammatory) macrophages was 
increased in NASH biopsies in comparison with SS ones (Table 2, p = 0.002), when histological diagnosis was 
taken into consideration (Table 2, Fig. 2C). The number of portal, but not lobular, S100A9+ macrophages was 
significantly correlated with NAS (r = 0.551; p = 0.000), fibrosis score (r = 0.472; p = 0.002), portal inflamma-
tion (r = 0.511; p = 0.001), DR (r = 0.479; p = 0.004), and the number of αSMA+ portal/septal MFs (r = 0.528; 
p = 0.001).
Histo-pathological and immunohistochemical parameters in PNPLA3 I148M variant carri-
ers. Liver biopsies were classified into wild type homozygous (WT: CC carriers; N = 15) and PNPLA3 I148M 
variant carriers (PNPLA3 variant carriers: GC/GG carriers; N = 39).
No difference between the two groups was present in term of Metabolic Syndrome (MetS) prevalence 
(Table 3). Overall, there were no differences in disease activity (NAS score) and stage (fibrosis score) when biop-
sies obtained from WT patients were compared to ones from PNPLA3 variant carriers (Table 3). However, biop-
sies from PNPLA3 variant carriers showed higher degree of steatosis (p = 0.022, Fig. 3), DR (p = 0.044, Fig. 4A), 
IH (p = 0.027), and a higher number of αSMA+ portal/septal MFs (p = 0.040, Fig. 4B) and portal S100A9+ mac-
rophages (p = 0.039, Fig. 4C) when compared with WT patients (Table 3). In biopsies with steatosis >0 obtained 
from PNPLA3 variant carriers, the steatosis distribution pattern was panacinar in 14, azonal in 10, zone 3 in 8, 
and zone 1 in 4 cases. Differently, in biopsies with steatosis >0 obtained from WT patients, steatosis distribution 
pattern was azonal in 5 and zone 3 in 5 cases, and panacinar in 1 case; only 1 biopsy was present in which steatosis 
was categorized as panacinar or zone 1 (p = 0.032 versus PNPLA variant carriers).
Portal inflammation was seen in 3/15 (20%) WT patients and in 23/39 (59%) PNPLA3 variant carriers 
(p = 0.015). Interestingly, when patients with MetS were separately considered (N = 32), biopsies from PNPLA3 
variant carriers (N = 23) still showed significantly higher degree of steatosis (p < 0.05), DR (p < 0.05), and portal 
inflammation (p < 0.05) when compared with WT patients (N = 9).
Then, liver biopsies were divided according to histologic classification into SS (N = 25) and NASH 
(N = 25). When SS biopsies were separately considered, PNPLA3 variant carriers showed higher DR extension 
(p = 0.014) and higher number of portal S100A9+ macrophages when compared with WT patients (p = 0.020) 
(Supplementary Table 1). Moreover, in NASH biopsies, PNPLA3 variant carriers showed higher degree of stea-
tosis (p = 0.025), portal inflammation (p = 0.034), DR (p = 0.036), EpCAM+ hepatocytes (p = 0.029), and higher 
number of αSMA+ portal/septal MFs (p = 0.011) when compared with WT patients (Supplementary Table 2).
SS (n = 25) NASH (n = 25) p-value
NAFLD activity score 2.73 ± 1.00 5.19 ± 1.18 0.000
Steatosis 1.08 ± 0.89 2.07 ± 0.87 0.000
Lobular inflammation 0.73 ± 0.53 1.63 ± 0.63 0.000
Ballooning 0.92 ± 0.80 1.48 ± 0.75 0.006
Portal inflammation (%) 32.0 64.0 0.023
Fibrosis score 1.38 ± 0.75 2.59 ± 0.80 0.000
Ductular Reaction 0.15 ± 0.13 0.50 ± 0.59 0.005
EpCAM+ hepatocytes 0.39 ± 0.58 0.96 ± 0.77 0.004
Pericentral αSMA+ HSCs 3.81 ± 3.86 6.39 ± 4.58 0.024
Portal/septal αSMA+ MFs 4.41 ± 3.47 7.09 ± 5.74 0.034
Lobular S100A9+ macrophages 8.80 ± 5.46 7.11 ± 3.78 0.113
Portal S100A9+ macrophages 2.51 ± 1.70 5.43 ± 3.72 0.002
Table 2. Histological and immunohistochemical findings. Data are reported as mean ± standard deviation. p 
value in bold are statistically significant. SS: simple steatosis; NASH: nonalcoholic steatohepatitis; HSCs: hepatic 
stellate cells; MFs: myofibroblasts; αSMA: α smooth muscle actin.
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Finally, biopsies from patients carrying PNPLA3 variant (N = 39) were subdivided in two groups according 
to the presence (N = 23) or absence (N = 16) of MetS. Biopsies from patients with MetS showed higher NAS 
(p = 0.000), lobular inflammation (p = 0.007), hepatocellular ballooning (p = 0.002), fibrosis score (p = 0.001), DR 
(p = 0.007), EpCAM+ hepatocytes (p = 0.011), αSMA+ portal/septal MFs (p = 0.045), and portal S100A9+ mac-
rophages (p = 0.020) when compared with patients without MetS (Table 4).
Serum oxidative stress. To investigate a potential mechanism responsible for the significant difference in 
histological features observed in NAFLD patients with and without PNPLA3 variant, we measured the activity of 
Nox2, a key enzyme producing reactive oxidant species that is directly implicated in liver fibrogenesis, and serum 
F2-Isoprostanes, a validated marker of oxidative stress15–18.
Serum Nox2 was correlated with NAS (r = 0.59; p < 0.001), DR (r = 0.36; p < 0.05), the number of 
αSMA+ pericentral HSCs (r = 0.40; p < 0.05) and αSMA+ portal/septal MFs (r = 0.51; p = 0.001), the degree 
Figure 1. Histo-pathological evaluation and fibrosis in non-alcoholic fatty liver disease biopsies. (A,B) 
Hematoxylin & Eosin (H&E) stain in A and Sirius Red/Fast green (SR/FG) stain in B in simple steatosis (SS) 
and definite steatohepatitis (NASH). NASH biopsies were characterized by a higher inflammation and fibrosis 
in comparison with SS. Original Magnification (OM) = 20x (A) and 10x (B). (C) Immunohistochemistry for α 
smooth muscle actin (αSMA). Higher number of αSMA-positive stellate cells/myofibroblasts was revealed in 
NASH when compared with SS biopsies. OM = 20x. Single hepatic stellate cell was magnified in the box (arrow).
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of steatosis (r = 0.37; p < 0.05) and lobular inflammation (r = 0.38; p < 0.05). Moreover, serum Nox2 was signif-
icantly correlated with hepatocellular ballooning (r = 0.36, p < 0.05) and portal, but not lobular, S100A9+ mac-
rophages (r = 0.42, p < 0.05).
Serum F2-isoprostanes were correlated with DR (r = 0.38, p < 0.05) and portal inflammation (r = 0.35; 
p < 0.05). A trend was also found for the number of αSMA+ pericentral HSC (r = 0.31; p = 0.051) and 
EpCAM+ hepatocytes (r = 0.30, p = 0.067).
Serum F2-isoprostanes were significantly higher in I148M variant carriers compared to non-carriers (p < 0.05, 
Table 1).
In a multivariable linear regression model, the association between F2-isoprostanes and I148M variant 
remained significant (beta = 0.34, p < 0.05) after adjustment for age, sex, smoking, number of components of 
MetS, and NAS.
Figure 2. Evaluation of ductular reaction and macrophage pool in non-alcoholic fatty liver disease biopsies. 
(A) Immunohistochemistry for Cytokeratin 7 (K7). Definite steatohepatitis (NASH) biopsies showed more 
extended ductular reaction if compared with simple steatosis (SS). Original Magnification (OM) = 10x. (B) 
Immunohistochemistry for Epithelial Cell Adhesion Molecule (EpCAM). NASH biopsies showed more 
numerous EpCAM+ hepatocytes (arrows) if compared with SS. OM = 20x. (C) Immunohistochemistry for 
S100A9. NASH biopsies were characterized by a higher number of S100A9-positive macrophages within the 
portal spaces (arrows) in comparison with SS. OM = 20x.
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Discussion
The main findings of the study indicate that NAFLD patients carrying PNPLA3 variant, compared to WT sub-
jects, showed: i) a more prominent portal/periportal pattern in liver damage, ii) a higher activation of HpSC 
niche, and iii) increased serum oxidative stress levels.
In the present study, patients with and without I148M variant did not differ in term of clinical parameters 
and histo-pathological staging (fibrosis) and grading (NAS) at liver biopsy. This aspect was essential to allow 
the comparison of the histologic pattern, HpSC niche activation, and oxidative stress levels, based on the pres-
ence/absence of PNPLA3 I148M variant. Patients carrying I148M variant disclosed higher values in hepatocyte 
Wild type (CC 
carrier) N = 15
PNPLA3 (GC/GG 
variant carrier) N = 39 p-value
NAFLD activity score 3.53 ± 1.68 4.15 ± 1.60 0.106
Steatosis 1.13 ± 0.99 1.74 ± 0.97 0.022
Lobular inflammation 1.33 ± 0.72 1.15 ± 0.94 0.223
Ballooning 1.07 ± 0.80 1.26 ± 0.82 0.401
Portal inflammation (%) 20 59 0.015
Fibrosis score 1.80 ± 1.08 2.10 ± 0.94 0.157
Ductular Reaction 0.12 ± 0.11 0.38 ± 0.49 0.044
EpCAM+ hepatocytes 0.33 ± 0.49 0.80 ± 0.76 0.027
Pericentral αSMA+ HSCs 3.93 ± 3.64 5.64 ± 4.60 0.124
Portal/septal αSMA+ MFs 3.57 ± 3.70 6.47 ± 5.13 0.040
Lobular S100A9+ macrophages 7.17 ± 3.03 8.14 ± 5.08 0.267
Portal S100A9+ macrophages 2.67 ± 1.91 4.71 ± 3.10 0.039
Table 3. Histological and immunohistochemical findings in NAFLD biopsies obtained from wild type 
homozygous patients and patients carrying PNPLA3 I148M variant. Data are reported as mean ± standard 
deviation. p value in bold are statistically significant. PNPLA3: patatin-like phospholipase domain containing 3; 
HSCs: hepatic stellate cells; MFs: myofibroblasts; αSMA: α smooth muscle actin.
Figure 3. Comparison of histo-morphological aspects between biopsies obtained from patients carrying or 
non-carrying non-synonymous variant I148M in human patatin-like phospholipase domain containing 3 gene 
(PNPLA3). Hematoxylin & Eosin (H&E) stain in upper images and Sirius Red stain in lower images. Patients 
with PNPLA3 variant were characterized by a higher steatosis and portal inflammation (asterisk) in comparison 
with wild-type (WT) patients. Original Magnification (OM) = 10x.
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steatosis and were characterized by the loss of a predominant pericentral damage location with higher steatosis 
in periportal hepatocytes and higher portal inflammation compared to WT subjects. The loss of function of 
lipase activity of PNPLA3 I148M variant promotes triglyceride accumulation, which can initially affect pericen-
tral hepatocytes2; this could induce further dynamic adaptation in fatty acid metabolism, resulting in the early 
progression of steatosis toward zone 1 within liver lobule19.
The higher accumulation or subcellular localization of several lipid compounds in PNPLA3 variant carriers 
may determine increased peroxidation and oxidative stress (lipotoxicity); lipotoxicity determines the increase 
of hepatocyte cell cycle arrest and apoptosis, thus leading to the subsequent activation of resident progenitor 
cell niche in NAFLD8,9. HpSCs are facultative stem/progenitor cells which become activated in several human 
liver diseases14. In NAFLD, HpSC activation follows the impairment of hepatocyte proliferation capabilities and 
Figure 4. Differences in ductular reaction, hepatic stellate cells/myofibroblasts and macrophage pool between 
biopsies obtained from patients carrying or non carrying non-synonymous variant I148M in human patatin-
like phospholipase domain containing 3 gene (PNPLA3). (A) Immunohistochemistry for Cytokeratin 7 (K7). 
Patients with PNPLA3 variant were characterized by a more extended ductular reaction if compared with WT 
patients. Original Magnification (OM) = 20x. (B) Immunohistochemistry for α smooth muscle actin (αSMA). 
Higher number of portal/periportal αSMA-positive myofibroblasts was revealed in patients with PNPLA3 
variant when compared with WT patients. OM = 10x. (C) Immunohistochemistry for S100A9. Patients with 
PNPLA3 variant were characterized by a higher number of S100A9-positive macrophages within the portal 
spaces (arrows) in comparison with WT patients. OM = 20x.
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is supported by a complex niche composed by macrophages, HSCs, and a well-defined extracellular matrix20. 
Interestingly, patients carrying I148M variant showed increased activation of HpSCs compared to WT subjects 
in terms of higher DR extension and presence of IH14. These differences were maintained when patients were 
divided according histological diagnosis (SS versus NASH), thus confirming their association with genetic variant 
independently from the diagnosis of NASH. Proliferating HpSCs are able to activate companion cells within the 
niche (i.e. HSCs and macrophages) via the production of a variety of growth factors, peptides and cytokines21,22. 
This interactions between HpSCs and companion cells establish pro-fibrogenic loops, resulting in progressive 
fibrosis14,20,23. Our results seem to be in accordance with this scenario; in patients carrying I148M variant HpSC 
activation and macrophage infiltration were already increased in SS and were followed by a more extensive portal 
myofibroblast activation in NASH. Remarkably, in previous and present studies, HpSC niche activation has been 
correlated with a worse NAFLD staging and grading, irrespectively to PNPLA3 genotyping8,9,13,24. Taken together, 
our results indicate that the loss of a predominant pericentral pattern of liver damage and the increased HpSC 
niche activation are key features in patients carrying I148M variant, independently to other clinical and histolog-
ical parameters. Our finding may explain, at least in part, the more aggressive course of liver disease observed in 
patients carrying PNPLA3 variant, as patients with portal fibrogenesis are more prone to develop progressive liver 
disease and liver-related mortality25–27.
Interestingly, previous studies indicated that PNPLA3 variants are associated with the severity of liver damage 
also in non-NAFLD patients including biliary diseases28. Thus, in biliary human diseases and in experimental 
models29, fibrosis is associated with biliary proliferation and ductular reaction. These parallel observations seem 
to suggest a common pathogenetic link between periportal hepatocyte injury and PNPLA3, irrespectively of 
disease aetiology and based on DR.
In this context, oxidative stress may represent a possible physio-pathologic link between PNPLA3 variant, 
histological pattern, and HpSC niche activation. Accordingly, our data indicated higher levels of serum oxidative 
stress markers in patients carrying PNPLA3 I148M variant compared to WT subjects and a significant correlation 
between HpSC activation and oxidative stress markers (i.e. F2-isoprostanes and Nox2 activity). Oxidative stress 
can trigger the activation of HpSC niche not only by causing hepatocyte cell cycle arrest but also by modulating 
the macrophage and HSC activity states8,9,30,31. To this latter regard, human quiescent HSCs express low levels of 
the catalytic subunits Nox2 and Nox1, which are highly up-regulated in vitro and in vivo from patients with liver 
fibrosis32. Nox mediates the fibrogenic responses to various agonists, including angiotensin II, platelet-derived 
growth factor leptin, transforming growth factor (TGF)-β, and advanced glycation end products; furthermore, 
Nox2 is involved in the activation of HSCs following phagocytosis of apoptotic hepatocytes by macrophages18. 
Previous study also showed that F2-isoprostanes generated by lipid peroxidation in hepatocytes mediate HSC 
proliferation and collagen hyperproduction seen in hepatic fibrosis33. Finally, PNPLA3 mutation has been showed 
to affect HSC activation by acting on vitamin A metabolism and increasing vitamin A retention inside the cells, 
thus reducing antioxidant availability34.
Besides I148M variant and oxidative stress, MetS represents a relevant clinical condition predisposing to 
NASH development and fibrosis35. In keeping, patients with I148M variant and MetS showed a more severe over-
all damaging, a more advanced staging, and a higher HpSC activation in comparison with patients without MetS.
Finally, it is interesting to note a lower prevalence of arterial hypertension in carriers of the I148M mutation, 
suggesting that in patients with genetic predisposition, the presence of cardio-metabolic risk factors is not always 
necessary to develop liver steatosis, as already reported in a large series of individuals with NAFLD36.
Our study has clinical and pathophysiologic implications. Patients with PNPLA3 I148M variant represent 
a subset of NAFLD patients at higher risk for liver damage, characterized by a particularly increased oxidative 
stress, which seems to play a key role in triggering the process of fibrosis. These patients may particularly benefit 
from a preventive strategy aimed to reduce oxidative stress and to a tight control of associated cardio-metabolic 
risk factors.
No MetS (n = 16) MetS (n = 23) p-value
NAFLD activity score 3.19 ± 1.42 4.83 ± 1.37 0.000
Steatosis 1.56 ± 1.15 1.87 ± 0.81 0.168
Lobular inflammation 0.81 ± 0.75 1.39 ± 0.65 0.007
Ballooning 0.81 ± 0.75 1.57 ± 0.73 0.002
Portal inflammation (%) 43.7 69.6 0.100
Fibrosis score 1.56 ± 0.73 2.48 ± 0.90 0.001
Ductular Reaction 0.15 ± 0.09 0.56 ± 0.59 0.007
EpCAM+ hepatocytes 0.47 ± 0.51 1.05 ± 0.83 0.011
Pericentral αSMA+ HSCs 4.35 ± 4.14 6.55 ± 4.78 0.080
Portal/septal αSMA+ MFs 4.77 ± 3.24 7.74 ± 5.94 0.045
Lobular S100A9+ macrophages 8.95 ± 5.18 7.54 ± 5.05 0.212
Portal S100A9+ macrophages 2.94 ± 1.93 5.56 ± 4.01 0.020
Table 4. Histological and immunohistochemical findings in biopsies from NAFLD patients carrying PNPLA3 
I148M variant with or without metabolic syndrome. Data are reported as mean ± standard deviation. p value in 
bold are statistically significant. MetS: metabolic syndrome; HSCs: hepatic stellate cells; MFs, myofibroblasts; 
αSMA: α smooth muscle actin.
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A limitation of the study is its cross-sectional design, as it does not allow to investigate if oxidative stress is 
associated with a more rapid/severe development of liver failure over time. An ad hoc longitudinal study is needed 
to clarify these aspects. Moreover, all patients who were included in the study were overweight/obese with a high 
prevalence of MetS; thus, further studies are needed to extend our findings to lean or normal weight NAFLD 
patients.
Finally, the association between specific pattern of liver fibrosis and other genetic variants should be further 
tested, as recent evidence suggested that, TM6SF2 p.E167K, and MBOAT7 rs641738 variants are associated with 
increased liver steatosis and fibrosis37.
In conclusions, NAFLD patients carrying PNPLA3 I148M variant are characterized by a specific histological 
pattern, higher HpSC niche activation and increased oxidative stress.
Materials and Methods
Patients. We included 54 patients with biopsy-proven NAFLD. Anthropometric data (i.e. waist circumfer-
ence and body mass index, BMI) and information on concomitant treatment and co-morbidities were registered. 
Routine clinical and biochemical evaluations were obtained for all patients. Inclusion criteria were: no history of 
current/past excessive alcohol drinking as defined by an average daily consumption of alcohol >20 g; negative 
tests for the presence of hepatitis B surface antigen and antibody to hepatitis C virus, BMI >24 Kg/m2. Exclusion 
criteria were evidence of chronic, progressive liver disease, active cancer and current supplementation with anti-
oxidants or vitamins. Cardiovascular and metabolic risk factors were defined as follows: arterial hypertension 
as repeated elevated blood pressure values (≥140/≥90 mmHg) or taking antihypertensive drugs38; diabetes as a 
casual plasma glucose ≥200 mg/dl (11.1 mmol/l), or fasting plasma glucose ≥126 mg/dl (7.0 mmol/l), or presence 
of anti-diabetic treatment39. Metabolic syndrome (MetS) was classified according to the modified criteria of the 
ATP III Expert Panel of the US-NCEP40.
Informed written consent was obtained and the study protocol conformed to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval by the local ethical board of Sapienza University of 
Rome41.
Liver biopsy and histo-pathological analysis. Percutaneous ultrasonography-guided liver biopsy was 
performed in NAFLD patients with persistent elevation of liver enzymes (>6 months). Liver biopsy was con-
ducted under conscious sedation using a 16-gauge Klatskin needle. Liver fragments were fixed in buffered forma-
lin for 2–4 hours and embedded in paraffin with a melting point of 55 °C–57 °C. Three- to 5-µm sections were cut 
and stained with hematoxylin and eosin and Sirius Red stains. A minimum biopsy specimen length of 15 mm or 
at least the presence of five complete portal tracts was required.
Histo-pathological evaluation has been performed on the basis of the NAFLD Clinical Research Network 
(CRN) criteria42. Features of steatosis (0–3), lobular inflammation (0–3), and hepatocyte ballooning (0–2) were 
combined to obtain the NAFLD activity score (NAS). Fibrosis score (0–4) was assigned based on Sirius Red 
stains42. As recommended43, a microscopic diagnosis based on overall injury pattern as well as the presence of 
additional lesions have been assigned to each case44. Biopsies were classified into simple steatosis with not-definite 
steatohepatitis (SS), definite steatohepatitis (NASH), borderline zone 1 pattern or borderline zone 3 pattern 
subcategories43.
Sections were examined with a Leica Microsystems DM 4500 B Microscopy (Weltzlar, Germany) equipped 
with a Jenoptik Prog Res C10 Plus Videocam (Jena, Germany) and were processed with an IAS—Delta Sistemi 
(Milan, Italy) and were independently scored by two researchers in double blind fashion.
Immunohistochemistry. For immunohistochemistry, endogenous peroxidase activity was blocked by a 
30-min incubation in methanolic hydrogen peroxide (2.5%). Antigens were retrieved, as indicated by the vendor, 
by applying Proteinase K (Dako, Glostrup, Denmark, code S3020) for 10 min at room temperature. Sections were 
then incubated overnight at 4 °C with primary antibodies against cytokeratin 7 (K7: mouse monoclonal; code: 
M7018; diluition: 1:50; Dako, Glostrup, Denmark), EpCAM (Dako Glostrup, Denmark, mouse monoclonal, 
code: M3525, dilution: 1:100), α Smooth Muscle Actin (αSMA: mouse monoclonal; code M0851; diluition 1:50; 
Dako, Glostrup, Denmark), and S100A9 (rabbit monoclonal; code: ab92507; diluition 1:200; Abcam, Cambridge, 
United Kingdom).
Then, samples were rinsed twice with phosphate buffered saline (PBS) for 5 minutes, incubated for 20 minutes 
at room temperature (RT) with secondary biotinylated antibody, and then with Streptavidin-horseradish per-
oxidase (LSAB+ , Dako, Glostrup, Denmark code K0690). Diaminobenzidine (Dako, Glostrup, Denmark code 
K3468) was used as substrate, and sections were counterstained with haematoxylin. For all immunoreactions, 
negative controls (the primary antibody was replaced with pre-immune serum) were also included45.
Slides were scanned by a digital scanner (Aperio Scanscope CS System, Aperio Digital Pathology, Leica 
Biosystems, Milan, Italy) and processed by ImageScope46. Only biopsies containing at least five portal spaces were 
considered.
The degree of HpSC activation was evaluated by the extension of ductular reaction (DR). The area occupied 
by DR was evaluated by K7 immunoreactivity, quantified by an image analysis algorithm, and was expressed as 
the percentage of the parenchymal area occupied by reactive ductules, as previously13. Cholangiocytes lining the 
interlobular bile ducts were excluded from the counts.
To assess the commitment of progenitor cells toward a hepatocyte fate, the presence of EpCAM+ hepatocytes 
has been investigated by immunohistochemistry. EpCAM+ hepatocytes have been shown to represent the prog-
eny of stem/progenitor cells within bile ductules. The presence of EpCAM+ hepatocytes was scored as: 0 = no 
positive cells, 1 (level 1) = single occasional, and 2 (level 2) = clusters of EpCAM+ hepatocyte13.
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The activation of Hepatic Stellate Cell (HSC)/Myofibroblast (MF) pool was evaluated by counting the num-
ber of αSMA-positive cells per high power field (HPF: at 40x). Perisinusoidal HSCs and portal/septal MFs were 
separately evaluated; αSMA-positive HSCs were recognized in accordance with their stellate/spindle shape 
and their perisinusoidal location within the parenchymal lobule; besides, portal/septal MFs were considered 
as stellate- or spindle-shaped αSMA-positive cells located at the interface between parenchyma and portal tract 
or between parenchyma and septa, and those residing in the portal tracts and the fibrotic septa. The number of 
αSMA-positive HSCs and MFs was counted and expressed as number of positive cells per HPF. For each slide, at 
least 10 non-overlapping microscopic HPFs were randomly chosen47.
The presence of macrophages with an inflammatory phenotype was calculated as the number of S100A9+ cells 
per HPF. For each slide, at least 10 non-overlapping microscopic HPFs were randomly chosen13.
Serum Nox2. To quantify NOX2 activity, we measured serum levels of soluble NOX2-derived peptide 
(sNOX2-dp), a marker of NOX2 activation, by ELISA method as previously described48 Blood samples were kept 
for 60 minutes at 37 °C and centrifuged at 300 g; serum was stored at −80 °C. Values were expressed as picograms 
per milliliter; intra-assay and inter-assay coefficients of variation were 5.2% and 6%, respectively.
Serum 8-isoprostaglandin F2α. Serum 8-isoprostaglandin F2α (8-isoPGF2α, F2-isoprostanes) levels 
were assessed by a previously described and validated EIA assay method and expressed as pg/ml49. Intra- and 
inter-assay coefficients of variation were 5.8% and 5.0% respectively.
Analysis of PNPLA3. DNA was extracted from peripheral blood and purified by the Wizard® Genomic 
DNA Purification Kit following the manufacturing protocol. Fluorogenic 5′-nucleotidase assays were developed 
to genotype the PNPLA3 rs738409 C to G non-synonymous sequence variant, encoding I148M, in all subjects. 
The assay was performed using the TaqMan C7241_10 assay (Applied Biosystems, Foster City, CA) on ABI 
PRISM 7900 HT Sequence Detection Systems. (Applied Biosystems, Foster City, CA). The plate was run using 
standard condition at 95 C for 10 min, 95 C for 15 s then 60 °C for 1 min for 40 cycles. Allele frequencies were 
in Hardy–Weinberg equilibrium. The TaqMan assay was validated by direct sequencing of the SNP (rs738409) 
in representative samples of DNA on ABI PRISM 3130 XL Genetic Analyzer, and both methods gave identical 
results.
Statistical Analysis. Categorical variables were reported as counts (percentage). Continuous variables were 
expressed as mean ± standard deviation or median and interquartile range. Normal distribution of parameters 
was assessed by Kolmogorov–Smirnov test. Student unpaired t test and Pearson correlation analysis were used 
for normally distributed continuous variables. Appropriate nonparametric tests (Mann-Whitney U test and 
Spearman rank correlation test) were employed for all the other variables. Categorical variables were compared 
using the Chi-squared test or Fischer’s Exact test as appropriate. All tests were two-tailed and a statistical signif-
icance was set at a p value of less than 0.05. Analyses were performed using computer software packages (IBM 
SPSS Statistics v20.0, Armonk, NY).
Sample size calculation. We computed the minimum sample size with respect to a two-tailed one-sample 
Student’s t-test, considering (i) as significant a difference in F2-isoprostanes of 8 pg/ml, (ii) a standard deviation 
of the paired differences of 6 pg/ml%, (iii) a type I error probability α = 0.05 and power 1-β = 0.90. This resulted 
in n = 24 (12 for each group).
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